CRISPR/Cas9 Editing of the C. elegans rbm-3.2 Gene using the dpy-10 Co-CRISPR Screening Marker and Assembled Ribonucleoprotein Complexes.
December 11th, 2020
6.9K views
The goal of this protocol is to enable seamless CRISPR/Cas9 editing of the C. elegans genome using assembled ribonucleoprotein complexes and the dpy-10 co-CRISPR marker for screening. This protocol can be used to make a variety of genetic modifications in C. elegans including insertions, deletions, gene replacements and codon substitutions.
Overview
This protocol outlines a method for CRISPR/Cas9 genome editing in C. elegans using ribonucleoprotein complexes and a co-CRISPR marker for effective screening. It enables various genetic modifications, including insertions and deletions.
Key Study Components
Area of Science
- Genetic Engineering
- Neuroscience
- Model Organisms
Background
- CRISPR/Cas9 is a powerful tool for genome editing.
- C. elegans serves as a model organism for genetic studies.
- Co-CRISPR markers enhance the identification of edited organisms.
- Efficient microinjection techniques are crucial for successful editing.
Purpose of Study
- To provide a streamlined protocol for genome editing in C. elegans.
- To demonstrate the use of co-CRISPR markers for screening edited worms.
- To facilitate various genetic modifications in a short time frame.
Methods Used
- Preparation of young adult C. elegans for microinjection.
- Assembly of ribonucleoprotein complexes for CRISPR editing.
- Microinjection of the CRISPR mix into the gonad arms of worms.
- Screening for edited progeny using phenotypic markers.
Main Results
- Identification of F1 progeny with desired genetic modifications.
- Successful recovery of edited worms exhibiting specific phenotypes.
- Confirmation of edits through PCR and restriction digestion analysis.
- Establishment of homozygous lines for further study.
Conclusions
- The protocol enables efficient genome editing in C. elegans.
- Co-CRISPR markers significantly improve screening success.
- Accurate microinjection and preparation are critical for outcomes.
Frequently Asked Questions
What is the main advantage of using co-CRISPR markers?
Co-CRISPR markers enhance the probability of identifying successfully edited worms.
How do you prepare C. elegans for microinjection?
Pick L2 or L3 stage worms onto a fresh bacterial lawn and incubate overnight.
What temperature is optimal for incubating the injection mix?
The injection mix should be incubated at 37 degrees Celsius for 15 minutes.
How can you confirm successful genome editing?
Successful editing can be confirmed through PCR and subsequent restriction digestion analysis.
What phenotypes indicate successful editing in C. elegans?
Roller and dumpy phenotypes are indicators of successful genetic modifications.
What is the importance of using a dissecting microscope?
A dissecting microscope is essential for accurately picking and injecting worms.
Executive Industry Relevance
This protocol enables rapid, precise genome editing in C. elegans using CRISPR/Cas9 ribonucleoprotein complexes and a co-CRISPR marker, supporting efficient target validation in discovery biology. The approach reduces timelines for generating loss-of-function models, facilitating mechanistic de-risking of therapeutic hypotheses. By improving editing efficiency and screening fidelity, it enhances predictive confidence in early-stage target assessment.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables interrogation of gene function through precise introduction of premature stop codons in rbm-3.2, supporting target hypothesis testing.
- Operational Value: Co-CRISPR screening with dpy-10 marker increases efficiency of identifying edited worms, reducing false-negative rates in mutant isolation.
- Predictive Value: Generation of homozygous-edited lines in under two weeks allows rapid phenotypic assessment for go/no-go decisions in target prioritization.
Screening & Assay Development
- Assay Readiness: Use of phenotypic markers (roller/dumpy) enables visual screening of F1 progeny, establishing a reproducible readout for editing efficiency.
- Quantitative Output: PCR and restriction digestion (EcoRI) provide measurable DNA fragment patterns (445 bp unedited, 265/166 bp edited) to quantify editing events.
- Scalability: Protocol supports processing of 30+ worms per injection, enabling medium-scale mutant generation for target panels.
Translational & Preclinical Research
- Disease Relevance: Edited rbm-3.2 lines can be used to study RNA-binding protein function in neurodegeneration models, aligning with preclinical target validation.
- Mechanistic De-risking: Confirmation of homozygous edits via sequencing reduces ambiguity in genotype-phenotype linkage, improving target confidence.
- Translational Continuity: Established homozygous lines support downstream phenotypic and expression analysis, bridging discovery to functional validation.
Pipeline & Workflow Integration
The method fits within the early discovery continuum, from target hypothesis to lead identification, by enabling rapid generation of genetic models for pathway and target validation.
- Discovery Biology: Supports hypothesis testing via targeted gene knockout, enabling functional assessment of rbm-3.2 in neuronal pathways.
- Screening: Phenotypic co-CRISPR marker (dpy-10) allows enrichment and visual identification of edited progeny, improving assay hit rates.
- Analytics: PCR-restriction digest assay delivers quantitative, binary readout of editing success, enabling comparison across conditions or guides.
- Translational Research: Homozygous mutant lines provide a defined genetic system for preclinical phenotypic screening and biomarker alignment.
- Enterprise Reuse: The RNP assembly and co-CRISPR strategy is adaptable to any C. elegans gene, supporting platform-wide reuse across target families.
Operational & Enterprise Impact
- Scientific Value: Precise genome editing reduces mechanistic ambiguity in target validation, increasing confidence in downstream pharmacological studies.
- Operational Value: Standardized RNP preparation and microinjection workflow improves reproducibility across users and labs.
- Strategic Value: Accelerated model generation (under two weeks) supports rapid target triage and reduces investment in low-confidence targets.
- Portfolio Impact: Enables risk-adjusted advancement by providing early functional evidence for target modulation in disease-relevant contexts.
Implementation Considerations
- Requires expertise in C. elegans handling, microinjection, and molecular biology techniques.
- Dependent on microinjection instrumentation and thermocycler for RNP assembly and PCR analysis.
- Needs standardization of worm staging, injection volume, and recovery conditions across operators.
- Adaptation to other genes requires redesign of gRNA and repair template while maintaining co-CRISPR marker consistency.
- Success depends on accurate microinjection into both gonad arms and proper lysis/PCR conditions to avoid false negatives.
Biopharma FAQs
Why does phenotypic screening with roller/dumpy markers matter for target validation?
The roller and dumpy phenotypes serve as co-CRISPR indicators that enrich for successfully edited F1 progeny, increasing the efficiency of identifying true positive mutations in the target gene.
How does isolating the independent variable (gRNA/template) improve discovery pipeline confidence?
By using a consistent co-CRISPR marker and varying only the gRNA and repair template for rbm-3.2, researchers can attribute phenotypic changes specifically to the target edit, reducing confounding variables in target validation.
What do quantitative dependent variable measurements (PCR/EcoRI fragments) enable in target assessment?
The shift from a single 445 bp fragment to dual 265/166 bp fragments upon EcoRI digestion provides a quantifiable, genotype-specific readout that confirms precise editing at the rbm-3.2 locus, supporting objective target modulation assessment.
Why do replication requirements (homozygous line confirmation) matter for cross-functional collaboration?
Confirming homozygous edits through F2 genotyping and sequencing ensures genetic uniformity, enabling reproducible phenotypic assays across biology, pharmacology, and toxicology teams in downstream target validation.
What statistical analysis capabilities are required before implementing this editing workflow?
Basic quantification of editing efficiency (e.g., ratio of positive F1 rollers to total injected) and Mendelian segregation ratios in F2 progeny are needed to assess editing robustness and guide scale-up decisions for target validation campaigns.
Chapters in this video
0:04
Introduction
0:53
C. elegans Gonad Preparation and Microinjection
1:56
Injected Worm Recovery and Transfer
2:37
PickingC. elegans for Screening
3:17
Single Worm Lysis and PCR
4:22
Restriction Digestion and Agarose Gel Electrophoresis
5:08
Identification of Positively Edited and Homozygous Edited Worms
6:01
Results: Representative C. elegans rbm-3.2 Gene Editing and Screening
7:10
Conclusion
